Daily flaxseed consumption improves glycemic control in obese men and women with pre-diabetes: A randomized study

Nutrition Research

Volumn 33, Issue 5, 2013, Pages 367-375

  Hutchins, Andrea M ^a   Brown, Blakely D ^b   Cunnane, Stephen C ^c   Domitrovich, Stephanie G ^b   Adams, Earle R ^b   Bobowiec, Courtney E ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Adults; Flaxseed; Glucose; Glycemic control; Inflammation; Insulin; Lignans; Men; Obesity; Omega 3 fatty acids; Overweight; Prediabetes; Randomized trial; Women

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FRUCTOSAMINE; GLUCOSE; HERBACEOUS AGENT; INSULIN; INTERLEUKIN 6; LINOLENIC ACID;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; LINSEED; MAJOR CLINICAL STUDY; MALE; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; AGED; ALPHA-LINOLENIC ACID; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIET; DIETARY SUPPLEMENTS; FASTING; FEMALE; FLAX; FRUCTOSAMINE; GLYCEMIC INDEX; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PREDIABETIC STATE;

EID: 84878150618     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2013.02.012     Document Type: Article

References (47)

1. Centers for Disease Control, Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
2. Anderson J.W. Nutritional management of diabetes mellitus. Modern nutrition in health and disease 1999, 1365-1394. Lippincot Williams and Wilkins, Philadelphia. M.E. Shils, J.A. Olson, M. Shike, A.C. Ross (Eds.).
3. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
4. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among U.S. adults, 1999-2008. JAMA 2010, 303:235-241.
5. Zozulinska D., Wierusz-Wysocka B. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract 2005, 74:S12-S16.
6. Nettleton J.A., Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 2005, 105:428-440.
7. Jenkins D.J., Jenkins A.L., Wolever T.M., Vuksan V., Rao A.V., Thompson L.U., et al. Low glycemic index: lente carbohydrates and physiological effects of altered food frequency. Am J Clin Nutr 1994, 59:706S-709S.
8. Oomah B.D., Mazza G. Flaxseed proteins: a review. Food Chem 1993, 48:109-114.
9. Hu C., Yuan Y.V., Kitts D.D. Antioxidant activities of the flaxseed lignan secoislariciresinol diglucoside, its aglycone secoislariciresinol and mammalian lignans enterodiol and enterolactone in vitro. J Chromatogr A 2007, 1185:223-232.
10. Adolphe J.L., Whiting S.J., Juurlink B.H.J., Thorpe L., Alcorn J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. Br J Nutr 2009, 103:929-938.
11. Cunnane S.C., Ganguli S., Menard C., Liede A.C., Hamadeh M.J., Chen Z.Y., et al. High α-linolenic acid flaxseed (Linum usitatissimum):some nutritional properties in humans. Br J Nutr 1993, 69:443-453.
12. Cunnane S.C., Hamadeh M.J., Liede A.C., Thompson L.U., Wolever T.M., Jenkins D.J. Nutritional attributes of traditional flaxseed in healthy young adults. Am J Clin Nutr 1995, 61:62-68.
13. Prasad K. Hydroxyl radical-scavenging property of secoisolariciresinol diglucoside (SDG) isolated from flaxseed. Mol Cell Biochem 1997, 168:117-123.
14. Kern P.A., Ranganathan S., Li C., et al. Adipose TNF and IL-6 expression in human obesity-associated insulin resistance. Diabetes 2000, 49(Suppl 1):A24.
15. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
16. Festa A., D-Agostino G., Howard G.L.M., Tracy R.P., Haffner S.M. Chronic sub-inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
17. Florez H., Castillo-Florez C., Mendez A., Casanova-Romero P., Larreal-Urdaneta C., Lee D., et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006, 71:92-100.
18. Frolich M., Imhof A., Berg G., Hutchinson W.L., Pepys M.B., Boeing H., et al. Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care 2000, 23:1835-1839.
19. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. An 8-year follow-up of 14719 initially healthy American women. Circulation 2003, 107:391-397.
20. Havel P.J. Section IV: lipid modulators of islet function; update on adipocyte hormones-regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004, 53(Suppl 1):S143-S151.
21. Miner J.L. The adipocyte as an endocrine cell. J Anim Sci 2004, 82:935-941.
22. Pellme F., Smith U., Funahashi T., Matsuzawa Y., Brekke H., Wiklund O., et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003, 52:1182-1186.
23. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004, 27:2450-2457.
24. Dodin S., S.C.C, Masse B., Lemay A., Jackques H., Asselin G., et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial. Nutrition 2008, 24:23-30.
25. Hallund J., Tetens I., Bugel S., Tholstrup T., Bruun J.M. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women. Nutr Metab Cardiovasc Dis 2008, 18:497-502.
26. Rhee Y., Brunt A. Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: A randomized, crossover design. Nutr J 2011, 10:44.
27. McCloy U., Ryan M.A., Pencharz P.B., Ross R.J., Cunnane S.C. A comparison of the metabolism of eighteen-carbon 13C-unsaturated fatty acids in healthy women. J Lipid Res 2004, 45:474-485.
28. Tiikkainen M., Hakkinen A.-M., Korsheninnikova E., Nyman T., Makimattila S., Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
29. Biarnes J., Fernandez-Real J.M., Fernandez-Castaner M., del Mar Garcia M., Soler J., Ricart W. Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin. Metab Clin Exp 2005, 54:235-239.
30. Hosoda K., Wang M.F., Liao M.L., Chuang C.K., Iha M., Clevidence B., et al. Antihyperglycemic effect of oolong tea in type 2 diabetes. Diabetes Care 2003, 26:1714-1718.
31. Jung H.S., Youn B.-S., Cho Y.M., Yu K.-Y., Park H.J., Shin C.S., et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metab Clin Exp 2005, 54:314-320.
32. Dodin S., S.C.C, Masse B., Lemay A., Jackques H., Asselin G., et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial. Nutr 2008, 24:23-30.
33. Pan A., Sun J., Chen Y., Ye X., Li H., Yu Z., et al. Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: A randomized, double-blind, cross-over trial. PLoS One 2007, 2:e1148.
34. Taylor C.G., Noto A.D., Stringer D.M., Froese S., Malcolmson L. Dietary milled flaxseed and flaxseed oil improve n-3 fatty acid status and do not affect glycemic control in individuals with well-controlled type 2 diabetes. J Am Coll Nutr 2010, 29:72-80.
35. Bloedon L.T., Bailikai S., Chittams J., Cunnane S.C., Berlin J.A., Rader D.J., et al. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr 2008, 27:65-74.
36. Jenkins A.L., Kendall C.W.C., Vidgen E., Agarwal S., Rao A.V., Rosenberg R.S., et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr 1999, 69:395-402.
37. Paschos G.K., Zampelas A., Panagiotakos D.B., Katsiougiannis S., Griffin B.A., Votteas V., et al. Effects of flaxseed oil supplementation on plasma adiponectin levels in dyslipidemic men. Eur J Nutr 2007, 46:315-320.
38. Zhang W., Wang X., Liu Y., Tian H., Flickinger B., Empie M.W., et al. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. Br J Nutr 2007, 99:1301-1309.
39. Ackermann D., Jones J., Barona J., Calle M.C., Kim J.E., LaPia B., et al. Waist circumference is positively correlated with markers of inflammation and negatively with adiponectin in women with metabolic syndrome. Nutr Res 2011, 31:197-204.
40. Hajri T., Tao H., Wattacheril J., Marks-Shulman P., Abumrad N.N. Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-α and interleukin-6. Am J Phys Endocrinol Metab 2011, 300:E350-E360.
41. Kampoli A.M., Tousoulis D., Briasoulis A., Latsios G., Papagerogiou N., Stefanadis C. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011, 17:4147-4158.
42. Meijer K., de Vries M., Al-Lahham S., Bruinenberg M., Weening D., Dijkstra M., et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS One 2011, 6:e17154.
43. Pan A., Demark-Wahnefried W., Xingwang Y., Zhijie Y., Li H., Qi Q., et al. Effects of a flaxseed-derived lignan supplement on C-reactive protein, IL-6 and retinol-binding protein 4 in type 2 diabetic patients. Br J Nutr 2009, 101:1145-1149.
44. Person T., Mensah G., Alexander R., Anderson J., Cannon R., Criqui M., et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
45. Fagerberg B., Kellis D., Bergstrom G., Behre C.J. Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women. J Intern Med 2011, 269:636-643.
46. Verkest K.R., Rand J.S., Fleeman L.M., Morton J.M., Richards A.A., Rose F.J., et al. Distinct adiponectin profiles might contribute to differences in susceptibility to type 2 diabetes in dogs and humans. Domest Anim Endocrinol 2011, 41:67-73.
47. Cunnane S.C., Ganguli S., Menard C., Liede A.C., Hamadeh M.J., Chen Z.Y., et al. High alpha-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans. Br J Nutr 1993, 69:443-453.